Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, MolecularMD Agree to Collaborate on Sequencing-Based Companion Diagnostics

NEW YORK (GenomeWeb) – MolecularMD said today that it has entered into an agreement with Illumina that establishes a framework for potential collaboration on next-generation sequencing-based companion diagnostics.

The companies did not disclose details of the agreement, but said that it would combine Illumina's NGS technology with MolecularMD's experience developing companion diagnostics and submitting products for US Food and Drug Administration clearance, with the goal of developing tests to support biopharmaceutical drug development programs.

MolecularMD opened its diagnostic laboratory in Cambridge, Massachusetts in 2012 and provides NGS solutions to support oncology clinical trials. It received CLIA certification and CAP accreditation in 2014, and had also adopted Thermo Fisher's Oncomine Cancer Research Panel and validated circulating tumor DNA analysis methods using Thermo Fisher's Ion AmpliSeq technology.

"The ability to collaborate with Illumina on defined projects will greatly aid our clients to mitigate risks and to accelerate their clinical trial programs," MolecularMD CEO Dan Snyder said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.